key: cord-0732530-11801t4j
authors: Lapp, S. A.; Edara, V. V.; Lu, A.; Lai, L.; Hussaini, L.; Chahroudi, A.; Anderson, L. J.; Suthar, M. S.; Anderson, E. J.; Rostad, C. A.
title: Original antigenic sin responses to heterologous Betacoronavirus spike proteins are observed in mice following intramuscular administration, but are not apparent in children following SARS-CoV-2 infection
date: 2021-04-30
journal: nan
DOI: 10.1101/2021.04.29.21256344
sha: a60755fcc550702f6bd0f8a3de539562154b81a7
doc_id: 732530
cord_uid: 11801t4j

Background: The effects of pre-existing endemic human coronavirus (HCoV) immunity on SARS-CoV-2 serologic and clinical responses are incompletely understood. Objectives: We sought to determine the effects of prior exposure to HCoV Betacoronavirus HKU1 spike protein on serologic responses to SARS-CoV-2 spike protein after intramuscular administration in mice. We also sought to understand the baseline seroprevalence of HKU1 spike antibodies in healthy children and to measure their correlation with SARS-CoV-2 binding and neutralizing antibodies in children hospitalized with acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome (MIS-C). Methods: Groups of 5 mice were injected intramuscularly with two doses of alum-adjuvanted HKU1 spike followed by SARS-CoV-2 spike; or the reciprocal regimen of SARS-Cov-2 spike followed by HKU1 spike. Sera collected 21 days following each injection was analyzed for IgG antibodies to HKU1 spike, SARS-CoV-2 spike, and SARS-CoV-2 neutralization. Sera from children hospitalized with acute COVID-19, MIS-C or healthy controls (n=14 per group) were analyzed for these same antibodies. Results: Mice primed with SARS-CoV-2 spike and boosted with HKU1 spike developed high titers of SARS-CoV-2 binding and neutralizing antibodies; however, mice primed with HKU1 spike and boosted with SARS-CoV-2 spike were unable to mount neutralizing antibodies to SARS-CoV-2. HKU1 spike antibodies were detected in all children with acute COVID-19, MIS-C, and healthy controls. Although children with MIS-C had significantly higher HKU1 spike titers than healthy children (GMT 37239 vs. 7551, P=0.012), these titers correlated positively with both SARS-CoV-2 binding (r=0.7577, P<0.001) and neutralizing (r=0.6201, P=0.001) antibodies. Conclusions: Prior murine exposure to HKU1 spike protein completely impeded the development of neutralizing antibodies to SARS-CoV-2, consistent with original antigenic sin. In contrast, the presence of HKU1 spike IgG antibodies in children with acute COVID-19 or MIS-C was not associated with diminished neutralizing antibody responses to SARS-CoV-2.

structurally similar boosting antigen. The mechanism of OAS is thought to be attributable to the 75 initial development and differentiation of memory B cells directed against the original antigen of 76 exposure. Upon secondary exposure to a structurally similar antigen, these memory B cells 77 undergo clonal expansion to preferentially produce antibodies directed against the original priming 78

antigen. The phenomenon of OAS has been well described with several other viruses including 79 dengue and influenza, and has led to concerns about its impact on disease severity and vaccine 80 development (9). 81

In this study, our objectives included determining if prior exposure to HKU1 spike protein 82 in a mouse model impacted serologic responses to SARS-CoV-2 upon spike protein challenge. 83

We further sought to determine the baseline seroprevalence of HKU1 spike antibodies in healthy 84 children and to assess if the presence or titer of HKU1 antibody affected the response to SARS-85

CoV-2 binding and neutralizing antibodies in children hospitalized with acute COVID-19 or 86 multisystem inflammatory syndrome (MIS-C). 87 88

Two groups of five BALB/c mice were injected intramuscularly (IM) with 10 µg each of 92 alum-adjuvanted full-length spike protein antigens according to the schedule shown in Figure 1 . 93

One group received a prime (d0) and boost (d21) with SARS-CoV-2 full-length spike protein, 94 followed by a prime (d42) and boost (d63) with HCoV HKU1 full-length spike protein. The second 95 group received a reciprocal immunization regimen of a prime and boost with HKU1 spike followed 96 by SARS-CoV-2 spike prime and boost. Submandibular bleed samples were collected at 3 weeks 97 following each injection, and a terminal bleed was performed 3 weeks following the last injection. 98 99 100 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. boost with HKU1 spike. Group 2 received a reciprocal administration regimen, with prime and 105

boost with HKU1 spike, followed by prime and boost by HKU1 spike. D, days post-administration; 106 S, spike; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. *These mice were 107 immunized with nucleocapsid protein 21 and 42 days prior to utilization for this study.

We measured IgG antibody titers to SARS-CoV-2 spike and HKU1 spike antigens in the 110 two groups of mice by ELISA. We also measured the neutralizing antibody titers of these plasma 111 samples using a Focus Reduction Neutralization Test (FRNT) with an infectious clone of SARS-112 CoV-2 virus (Wuhan strain, A.1 based on PANGO lineage) as previously described (10, 11) (Fig  113   2 ). As expected, the SARS-CoV-2 spike-primed mice developed SARS-CoV-2 spike IgG 114 antibodies that significantly increased in titer after the first injection (1914 vs. 85, P=0.012) and 115 peaked at 21 days after the SARS-CoV-2 spike boost (139316 vs 85, P<0.001, Fig 2A) . The 116 SARS-CoV-2 spike IgG antibody titers did not further increase after subsequent administration of 117 HKU1 spike. The HKU1 spike-primed mice also generated cross-reactive anti-SARS-CoV-2 spike 118

IgG antibodies that reached statistical significance on day 21 post-HKU1 spike boost (2594 vs. 119 85, P=0.018, Fig 2B) . Subsequent injection with SARS-CoV-2 spike incrementally boosted SARS-120 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Fig 2D) . Subsequent injection with 130 SARS-CoV-2 spike protein did not further increase HKU1 spike IgG titers. 131

We then performed SARS-CoV-2 neutralizing FRNT antibody assays with these samples 132 using an infectious clone of SARS-CoV-2. Only the SARS-CoV-2 spike primed mice generated 133 neutralizing antibodies to SARS-CoV-2 ( Fig 2E) . Neutralizing titers significantly increased 134 compared to baseline after the boost immunization of SARS-CoV-2 spike (180 vs. 31, P=0.006) 135 and further increased following the second HKU1 spike boost (520 vs. 180, P=0.050), 136 demonstrating that HKU1 spike boosted neutralizing antibodies to SARS-CoV-2. In contrast, the 137 HKU1 spike/SARS-CoV-2 prime-boosted mice did not generate neutralizing antibodies to SARS-138

CoV-2 following any administration of antigen ( Fig 2F) . Thus, recent prior exposure to the endemic 139 

Because our mouse data suggested that prior exposure to endemic coronaviruses may 159 blunt serologic responses to SARS-CoV-2 by the phenomenon of original antigenic sin, we next 160 measured the baseline seroprevalence of IgG antibodies to both SARS-CoV-2 and HKU1 spike 161 proteins in healthy children (n=14) using pre-pandemic sera. The healthy, asymptomatic children 162 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256344 doi: medRxiv preprint were recruited from the community to participate in a phlebotomy study between 2016-2018, and 163 they were comprised of 10 females (71%), median age 8 years (IQR 2.3-11.8 years), 8 (57%) 164

Black, 4 (29%) White, 2 (14%) other race, and 14 (100%) non-Hispanic ethnicity. The geometric 165 mean antibody titers from healthy children were then compared to children hospitalized at 166

Children's Healthcare of Atlanta with acute COVID-19 (n=14) or MIS-C (n=14) (Table 1, Figure 3 ) 167 using one-way analysis of variance (ANOVA) of log-transformed titers. 168 169 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2021. 

As expected, we found significantly higher SARS-CoV-2 spike IgG titers in children with 177 acute COVID-19 (7727 vs. 1019, P<0.001) and MIS-C (46989 vs. 1019, P<0.001) compared to 178 healthy controls ( Fig 3A) . Moreover, children with MIS-C had significantly higher SARS-CoV-2 179 spike IgG titers compared to those with acute COVID-19 (Fig 3A, P<0 .001), as we have previously 180 shown (12). All healthy controls had detectable antibodies to HKU1 spike with a wide range of 181 titers (GMT 7551, 95% CI 3317 to 17190, Fig 3B) . We found no difference in HKU1 spike IgG 182 titers between healthy controls and children with COVID-19 (7551 vs. 9376, P=0.917), but children 183

with MIS-C had significantly higher HKU1 spike IgG titers compared with healthy children (37239 184 vs. 7551, P=0.012) and those with acute COVID-19 (37239 vs. 9376, P=0.043, respectively). 185

We then tested the ability of plasma from the groups of children to neutralize an infectious 186 clone of the SARS-CoV-2 virus using the FRNT assay. Plasma from healthy controls failed to 187 neutralize SARS-CoV-2. In contrast, plasma from children with acute COVID-19 (33 vs. 10 (lower 188 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this study, we found that priming mice with an endemic coronavirus HKU1 spike protein 221 impeded the development of neutralizing antibodies to SARS-CoV-2 upon challenge with SARS-222

CoV-2 spike, consistent with original antigenic sin (OAS). Boosting mice intramuscularly with the 223 heterologous coronavirus adjuvanted spike protein appeared to preferentially boost antibodies 224 directed at the priming spike protein at shared, non-neutralizing epitopes. The phenomenon of 225 OAS has been described in humans and animals with influenza (13, 14), dengue (15, 16), and 226 human rhinovirus (17). The pathophysiology of OAS is thought to be attributable to sequential 227 exposure to similar, but non-identical antigens which preferentially elicits antibodies to the original 228 antigen due to immunologic memory B cells (9). Our data provides evidence that OAS plays a 229 role in the murine serologic response to the spike protein of coronaviruses upon sequential 230

In contrast, analysis of clinical specimens from children with COVID-19 and MIS-C 232 suggests that the serologic responses to SARS-CoV-2 in children may be amoral. Healthy 233 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2021. 

Six to 8-week-old female BALB/c mice were obtained from Jackson Laboratory (Bar 279

Harbor, ME) and housed in pathogen-free conditions. All animal experiments were conducted 280 according to approved protocols by the Emory University Institutional Animal Care and Use 281 Committee (PROTO202000026). 282

One group of five Balb/c mice was primed and boosted at 21 days IM with 10 µg SARS-283

CoV-2 nucleocapsid protein (SinoBiological, 40588-V08B) in 50 µl with alum (Alhydrogel adjuvant 284 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256344 doi: medRxiv preprint 2%, Invivogen). The purpose of this was to generate polyclonal antiserum to the nucleocapsid 285 protein early during the COVID-19 pandemic, which was not a part of the present study. These 286 mice were immunized 3 weeks later analogously with 10 µg alum-adjuvanted HCoV-HKU1 S1+S2 287 ECD-His (SinoBiological, 40606-V08B) IM, followed by an identical boost 21 days later. Three 288 weeks later the same mice were immunized with 10 µg alum-adjuvanted SARS-CoV-2 S1+S2 289 ECD-His (SinoBiological, 40589-V08B1) IM, followed by a final boost 21 days later. Plasma was 290 collected by submandibular bleeding on day 21 following each administration. A terminal bleed 291 via cardiac puncture was conducted 21 days after the final boost. 292

A second group of five mice was immunized with 10 µg alum-adjuvanted SARS-CoV-2 293 S1+S2 ECD-His followed by a boost 21 days later. The mice were immunized 3 weeks later with 294 10 µg alum-adjuvanted HCoV-HKU1 S1+S2 ECD-His, followed by a boost 21 days later. Blood 295 was collected as described above. Serum samples from each group were pooled and all serologic 296 analyses were performed on pooled samples in duplicate. 297

Children and adolescents, 0 to 21 years of age, hospitalized at Children's Healthcare of 299 Atlanta (CHOA) with confirmed or suspected COVID-19 or MIS-C were enrolled into an IRB-300 approved specimen collection protocol (Emory University IRB protocols STUDY00022371 and 301 STUDY00000723) following written or verbal informed consent and assent as appropriate for age 302 as previously described (12). The Emory University IRB approved obtaining verbal consent and 303 assent under specific circumstances, including to limit staff exposure to COVID-19. If verbal 304 consent and assent were obtained, this was documented on the approved ICF form by the staff 305 member who obtained consent. Children were classified as having MIS-C if they met the Centers 306

for Disease Control and Prevention case definition (22). They were classified as having acute 307 COVID-19 if they were hospitalized with symptomatic disease and had SARS-CoV-2 detected by 308 nasopharyngeal (NP) real-time polymerase chain reaction (RT-PCR). Prospective blood samples 309 were collected from patients at the time of enrollment, and residual samples leftover from clinical 310 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256344 doi: medRxiv preprint labs were also obtained from the clinical laboratory. Plasma from healthy pediatric controls was 311 collected through a separate IRB-approved protocol (STUDY0008846) following written informed 312 consent and assent, as appropriate for age. Partial non-HKU1 serologic data from a subset of 313 these children (4 with acute COVID-19 and 7 with MIS-C) were included in a prior publication (12). 314

Of the 126 planned analyses (3 groups, 14 patients per group, 3 types of serologic assays), there 315 was insufficient volume to complete 5 assays. Data is available in the supporting information. Reactions were incubated for 5 minutes then stopped with 1 M HCl and absorbance was 332 measured at 490 nm. 333

FRNT assays were performed as previously described (11). Briefly, samples were diluted at 3-fold 335 in 8 serial dilutions using DMEM (VWR, #45000-304) in duplicates with an initial dilution of 1:10 in a total 336 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. boost with HKU1 spike, followed by prime and boost by HKU1 spike. D, days post-administration; 362 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 30, 2021. ; https://doi.org/10.1101/2021.04.29.21256344 doi: medRxiv preprint S, spike; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. *These mice were 363 immunized with nucleocapsid protein 21 and 42 days prior to utilization for this study. 364 

Endemic Non-SARS-CoV-2 Human Coronaviruses in a 415 Community-Based Australian Birth Cohort

Characteristics and Outcomes 417 of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State

Antibody against nucleocapsid 420 protein predicts susceptibility to human coronavirus infection

Development and Evaluation of 422 a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human 423

Serologic 425 cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses

A 428 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, 429 and association with severity

Reduced development of COVID-19 in 431 children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics

Preexisting and de novo 434 humoral immunity to SARS-CoV-2 in humans

Original antigenic sin: A 436 comprehensive review

Rapid 438 Generation of Neutralizing Antibody Responses in COVID-19 Patients

Development of 440 a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies

Serology in Children With Multisystem Inflammatory Syndrome (MIS-C)

Strategies to alleviate original antigenic sin responses to 446 influenza viruses

Epidemiologic and immunologic significance of age 448 distribution of antibody to antigenic variants of influenza virus

Original antigenic sin in dengue

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

A polyvalent inactivated 455 rhinovirus vaccine is broadly immunogenic in rhesus macaques

Seasonal human 457 coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Recent endemic coronavirus 460 infection is associated with less-severe COVID-19

The dominance of 462 human coronavirus OC43 and NL63 infections in infants

466 22. CDC Health Alert Network. Multisystem inflammatory syndrome in children (MIS-C) associated 467 with coronavirus disease 2019 (COVID-19)

We thank clinical research coordinators Beena Desai, Kerry Dibernardo, Felicia Glover, Vikash 385

Stephens for their assistance enrolling patients and collecting specimens. We thank Nadine 387